Formulating a national position statement and guide on modern theranostics in the Philippines

Document Type : History and perspective


1 St. Luke’s Medical Center - Global City, Philippines

2 Our Lady of Mt. Carmel Medical Center, Pampanga, Philippines

3 Veterans Memorial Medical Center, Quezon City, Philippines

4 St. Luke's College of Medicine, Quezon City, Philippines


Barriers to the establishment of advanced technologies in developing countries were overcome when modern theranostics pertaining to the use of Ga-68 and Lu-177 PSMA and DOTATATE were first offered to patients in the Philippines in early 2018. However, significant growth was not experienced at St. Luke’s Medical Center for five years and lutetium was not yet distributed to other institutions by a radiopharmaceutical supplier. Due to the relative novelty and rapid expansion of theranostics worldwide, position statements were released by the Australasian Association of Nuclear Medicine Specialists, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and International Atomic Energy Agency primarily to uphold patient safety and ensure a level of standard among its practitioners. Subsequently in the latter half of 2022, these were adopted and modified according to what is feasible and applicable locally within the Philippine Society of Nuclear Medicine, considering the current status and future possibilities. Different representatives were involved, and several groups were mobilized for successful implementation. A liability clause was incorporated to discourage unprofessional acts.


Main Subjects

  1. Bautista PA. The emergence of theranostics in the Philippines: overcoming challenges and bringing hope. Nucl Med Mol Imaging. 2019; 53(1): 30-32.
  2. Australasian Association of Nuclear Medicine Specialists (AANMS) Position Statement on the Practice of Theranostics in Australia (Version 1, February 2021) In: Theranostics, Australasian Association of Nuclear Medicine Specialists. https:// aanms. 2022.
  3. Lee ST, Emmett L, Pattison DA, Hofman MS, Bailey DL, Latter MJ, et al. The importance of training, accreditation and guidelines for the practice of theranos-tics: the Australian perspective. J Nucl Med. 2022; 63(6):819-822.
  4. Herrmann K, Giovanella L, Santos A, Gear J, Kiratli PO, Kurth J, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. Eur J Nucl Med Mol Imaging. 2022; 49(7):2300-2309.
  5. Revised Regulation: CPR Part13, “Licenses for Medical Use of Unsealed Radioactive Material” Department of Science and Technology, Philippine Nuclear Research Institute, Nuclear Regulatory Division. 2014. https://pnri.
  7. Herrmann K, Larson SM, Weber WA. Theranostic concepts: more than just a fashion trend – introduction and overview. J Nucl Med. 2017; 58:1S-2S.
  8. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997; 7(2):163-76.
  9. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001; 28(12):1751-7.
  10. Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy – the Bad Berka Theranostics. 2012; 2(5):437-447.
  11. Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, et al. How we do it: A multidisciplinary approach to 177Lu-DOTATATE peptide receptor radionuclide therapy. Radiology. 2021; 298:261–274.